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Use of Serum Homocysteine to Predict Cardiovascular Disease  
in Korean Men with or without Metabolic Syndrome
The aim of this study was to examine whether serum homocysteine (Hcy) levels correlated 
with cardiovascular disease (CVD) depending on the presence or absence of metabolic 
syndrome (MetS) in Korean men. We conducted a case-control study, including 138 CVD 
and 290 non-CVD age-matched control subjects. The subjects were divided into four 
subgroups: 34 CVD/MetS, 104 CVD, 77 MetS, and 213 normal subgroups. The mean Hcy 
was significantly higher, whereas HDL and intake of vitamin B1 and B2 were lower in the 
CVD group (P < 0.05) than non-CVD group. When compared to the control group, 
subjects with CVD/MetS, CVD and MetS exhibited high Hcy levels, with the highest 
observed in the CVD/MetS subgroup (P < 0.001). Multivariate stepwise linear regression 
between CVD and markers of CVD showed Hcy significantly correlated with CVD (P < 0.05). 
To predict CVD based on Hcy, Hcy threshold of 11.72 µM in non-MetS subjects had an area 
under the curve (AUC) of 0.664 (95% CI 0.598-0.731). In MetS subjects, the AUC was 
0.618 and Hcy threshold was 13.32 μM (95% CI 0.509-0.726). The results of our study 
show that the presence of MetS needs to be considered when using Hcy levels for 
predicting CVD. 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Traditional risk factors for cardiovascular disease (CVD), such 
as diabetes mellitus, dyslipidemia, hypertension, smoking and 
low physical activity have been used to assess the risk of CVD (1, 
2). However, these characteristics do not fully explain cardiovas-
cular risk. Therefore, there has been a focus on newly identified 
risk factors such as increased plasma homocysteine (Hcy), C-
reactive protein (CRP), B-type natriuretic peptide level, and met-
abolic syndrome (MetS) (3, 4). 
  Although the mechanism that explains the relationship be-
tween elevated plasma Hcy levels and CVD is unclear, Hcy is a 
strong and independent risk factor for CVD, particularly coro-
nary heart disease, stroke and atherosclerosis (5, 6). Common-
ly, hyperhomocysteinemia was defined with a Hcy level above 
12 μM (7) or 15 μM (8). Some studies quantified the Hcy levels 
as quartile (6, 9) or quintile (10), and compared above and be-
low 12 μM (7). Subsequently, the contribution of Hcy to the pre-
diction or diagnosis on CVD is still undetermined.
  MetS is known as a cluster of cardiovascular risk factors asso-
ciated with insulin resistance, hypertension, glucose intoler-
ance, hypertriglyceridemia and low levels of HDL, and is the 
concurrence of multiple metabolic abnormalities in an individ-
ual (11). MetS is associated with increased cardiovascular events 
and death (4), and is a cardiovascular risk factor, but not an in-
dependent predictive index along with diabetes, obesity, dys-
lipidemia, and smoking. Therefore, Wang et al. (3) stated the 
importance of putative biomarkers to standard risk factors for 
CVD risk assessment of individuals.
  The Skaraborg project found a significant association between 
Hcy and insulin resistance index including serum insulin and 
HOMA-IR, and provided a potential link between MetS and hy-
perhomocysteinemia (12). In previous studies using Korean 
adults, MetS and its components were shown to have a signifi-
cant correlation with a high level of Hcy (9, 13). However, the 
Persian Gulf Healthy Heart Study (14) indicated that no associ-
ation between MetS using NCEP-ATP III criteria and Hcy. Fur-
thermore, a few studies have shown that Hcy levels were not dif-
ferent based on the presence of MetS using NCEP-ATP III crite-
ria in Korean type 2 diabetes patients (15, 16). There is contro-
versy concerning the usefulness of Hcy based on whether the 
patient has MetS, but, no comprehensive study was performed 
on the predictive values of Hcy for CVD in subjects with or with-
out MetS so far. 
  Therefore, in the present study, we investigated the associa-
tion of Hcy with CVD and MetS and proposed optimal cut-off 
points for the prediction of CVD based on MetS. Kang JY, et al.  •  Homocysteine to Predict CVD with or without Mets
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MATERIALS AND METHODS
Subjects and study design 
This was a retrospective case-control study, in which 4,043 indi-
viduals without pre-existing CVD between the ages of 40 to 59 yr 
participated in annual regular health check-ups in 2008. 3,886 
of 4,043 individuals were participated health follow-up in 2009 
and 2010. A total of 138 CVD patients who were newly diagnosed 
with CVD in 2009 or 2010 were included in this study and clas-
sified as the CVD group. The incidence of CVD cases were de-
fined as fatal and nonfatal myocardial infarction, stroke, angina, 
heart failure, peripheral vascular event, revascularization (coro-
nary artery bypass surgery or angioplasty with or without stent-
ing) and CVD-related hospital admissions. Age- and the num-
ber of MetS components non-CVD group, who were recruited 
and provided informed consent, consisted of 290. The subjects 
were assigned in about 2:1 ratio to either the non-CVD group or 
CVD group. Finally, non-CVD and CVD groups were divided 
into four subgroups depending on the presence of MetS. In to-
tal, 428 men were included in the final analyses: 213 normal 
subgroup, 77 MetS subgroup, 104 CVD subgroup, and 34 CVD/
MetS subgroup.
 
Measurements
Anthropometry of each subject was conducted by experienced 
research staff. Height and weight were measured with the sub-
ject standing straight wearing light clothing (InBody 720; Bio-
space, Seoul, Korea). Body mass index (BMI) was calculated as 
body weight in kilograms divided by height in meters squared 
(kg/m
2). Waist circumference (WC) was obtained at midpoint 
between the anterior superior iliac crest and lower rib. Blood 
pressure was recorded in duplicate in a sitting position after 15 
min of rest using a sphygmomanometer and the results were 
averaged. 
  Blood samples were collected from subjects for all biochemi-
cal evaluations after fasting for over 12 hr. Fasting plasma glucose 
(FPG), total cholesterol (TC), triglyceride (TG), high density lipo-
protein cholesterol (HDL) and low density lipoprotein choles-
terol (LDL) were measured using enzymatic methods (Cobas 
Integra 800; Roche Diagnostics, Mannheim, Germany). Hcy and 
creatine (CRE) were measured by enzyme-linked immune-sor-
bent assays (ELISA) using Alisei Quality system (SEAC, Calenz-
ano, Italy).   
  Typical dietary intake was analyzed using a computerized 
food frequency questionnaire (FFQ). The FFQ consisted of 7 food 
groups including 108 food items and was based on the FFQ de-
veloped by the Korea Center for Disease Control and Preven-
tion. It was designed to collect information regarding the usual 
intake of food over the past one year.  
  The subjects also completed a computerized self-adminis-
tered questionnaire regarding their health-related variables that 
included smoking status, alcohol drinking habit and exercise.
  We analyzed using the indices of anthropometry and blood 
sample, and results of FFQ and self-administered questionnaire 
for 2008.  
Definition of MetS 
A diagnosis of the MetS was based on modified ATP III defini-
tion, in which three of the following five criteria need to be sat-
isfied (17):
1) WC: a modified cut-off point of 90 cm for Asia-Pacific men, 
which is consistent with recommendations from WHO 
Expert Consultation (18)
2) blood pressure: a systolic blood pressure (SBP)  ≥ 130 
mmHg or a diastolic blood pressure (DBP)  ≥ 85 mmHg 
or on drug treatment for hypertension 
3) TG:  ≥ 150 mg/dL (1.7 mM) or on drug treatment for ele-
vated TG 
4) HDL:  < 40 mg/dL (1.0 mM) or on drug treatment for re-
duced HDL
5) FPG:  ≥ 100 mg/dL (5.6 mM) or on drug treatment for ele- 
vated FPG
 
Statistical analyses
For determining sample size statistical software package G*Power 
(version 3.0.10, Franz Faul, Universität Kiel, Germany) was used. 
A total of 400 subjects were calculated as a sample size for α = 0.05 
and 95% power among four groups in a fixed-effects ANCOVA 
model with a two-sided. 
  All statistical analysis was performed using SPSS for Windows, 
version 18.0 (SPSS Inc., Chicago, IL, USA). All values are pre-
sented as the mean ± standard deviation or number (%). Differ-
ences between the two groups were analyzed by an indepen-
dent Student’s t-test or chi-square test. In addition, markers of 
CVD among four groups were assessed by ANOVA and analysis 
of covariance after adjustment for age (ANCOVA). Pearson’s cor-
relation and partial correlation were used to examine the asso-
ciation of Hcy and cardiovascular risk factors. Stepwise multiple 
regression analysis was then used to evaluate the independent 
associations of these variables in non-MetS and MetS. Sensitiv-
ity and specificity of the Hcy criteria to detect CVD were calcu-
lated. Based on the receiver operating characteristic (ROC) anal-
ysis, the best cut-off point of Hcy was determined from the high-
est Youden index, which was defined as follows: sensitivity + 
specificity-1) (19). All reported P values were two-tailed, and 
the statistical significance was set at P < 0.05.
Ethics statement
This study was approved by the institutional review board of the 
Asan Medical Center (IRB No. 2007-0119). Informed written 
consent was obtained from all subjects following the contents 
of the study. Kang JY, et al.  •  Homocysteine to Predict CVD with or without Mets
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RESULTS
Table 1 shows the general and clinical characteristics of the 428 
study subjects (290 CVD and 138 non-CVD). Compared with 
the non-CVD group, the CVD group had significantly lower val-
ue for HDL and dietary intake of vitamin B1 and B2 (HDL, P =  
0.001; vitamin B1, P = 0.040; vitamin B1, P = 0.023). Also, Hcy 
concentration was significantly higher in the CVD group (P <  
0.001). There were no significant difference in age, BMI, SBP, 
DBP, WC, FPG, TC, TG, LDL, MetS, smoking, drinking, and ex-
ercise between the two groups (Table 1).
  Compared with the control group, the mean age of MetS and 
CVD/MetS groups were significantly higher (P < 0.001). BMI, 
SBP, DBP, WC, TC, and TG were higher in CVD and CVD/MetS 
subgroups than in the control and MetS subgroup (P < 0.001). 
In the CVD/MetS subgroup, HDL was significantly lower (P <  
0.001) and FPG and Hcy were significantly higher than the nor-
mal subgroup (P < 0.001). In addition, LDL was the highest in 
the CVD/MetS subgroup (Table 2). However, the dietary intakes 
of B vitamins (folate, B1, B2 and B6) were similar across the sub-
groups.
  Correlations were analyzed between Hcy and cardiovascular 
risk factors (Table 3). Hcy demonstrated a statistically significant 
positive correlation with age (r = 0.175, P < 0.001), BMI (r = 0.151, 
P = 0.002), SBP (r = 0.148, P = 0.002), DBP (r = 0.157, P = 0.001), 
WC (r = 0.142, P = 0.003), FPG (r = 0.121, P = 0.012), TC (r =  
0.118, P = 0.015), TG (r = 0.174, P < 0.001) and CRE (r = 0.100, 
P = 0.039) and negative correlation with HDL (r = -0.120, P =  
0.013). Adjustment for age did not alter the results (Table 3). 
  In Table 4, stepwise linear regression analysis using Hcy showed 
a significant positive coefficient for CVD both in non-MetS sub-
jects (β = 0.041, P < 0.001) and MetS subjects (β = 0.027, P =  
0.034). Adjustment for age did not alter the results (Table 4).    
  Fig. 1 shows the ROC curve for Hcy value prediction CVD 
Table 1. Demographic and clinical characteristics of subjects
Parameters
Non-CVD group  
(n = 290)
CVD group  
(n = 138)
P value
Age (yr)   50.44 ± 3.79    50.32 ± 4.06  0.772
Body mass index (kg/m
2)   24.16 ± 2.54    24.34 ± 2.37  0.477
Systolic blood pressure (mmHg) 124.31 ± 13.56  126.09 ± 15.24  0.243
Diastolic blood pressure (mmHg)   82.11 ± 9.77    83.93 ± 10.40  0.086
Waist circumference (cm)   84.39 ± 6.66    83.64 ± 6.75  0.282
Fasting plasma glucose (mg/dL)   98.64 ± 22.89    99.85 ± 19.93  0.578
Total cholesterol (mg/dL) 194.61 ± 35.18  198.01 ± 32.54  0.327
Triglyceride (mg/dL) 144.77 ± 82.99  158.16 ± 127.78  0.263
HDL (mg/dL)   50.93 ± 13.46    46.71 ± 10.99  0.001
LDL (mg/dL) 126.79 ± 33.91  131.75 ± 29.97  0.126
Homocysteine (µM/L)   11.45 ± 3.23    13.47 ± 3.82  < 0.001
Creatinine (mg/dL)     0.84 ± 0.11      0.84 ± 0.11  0.581
Dietary folate intake (µg/d)  418.98 ± 202.65 386.93 ± 192.56 0.115
Dietary vitamin B1 intake (mg/d)     2.04 ± 1.36     1.76 ± 1.28 0.040
Dietary vitamin B2 intake (mg/d)     1.82 ± 1.08     1.58 ± 1.02 0.023
Dietary vitamin B6 intake (mg/d)     2.44 ± 1.19     2.26 ± 1.32 0.194
Metabolic syndrome
   No
   Yes
 
213 (73.4)
  77 (26.6) 
 
104 (75.4) 
  34 (24.6) 
 
0.724
Smoking 
   Non-smoker
   Current smoker
 
211 (72.8) 
  79 (27.2) 
 
  95 (68.8)
  43 (31.2) 
 
0.424
Drinking
   Non-drinker
   Current drinker
 
17 (5.9) 
273 (94.1) 
 
  7 (5.1) 
131 (94.9) 
 
0.825
Exercise
   No
   Yes
 
26 (9.0) 
264 (91.0) 
 
11 (8.0) 
127 (92.0) 
 
0.855
Data are mean ± standard deviation or n (%). HDL, high density lipoprotein choles-
terol; LDL, low density lipoprotein cholesterol.
Table 2. Comparison of markers of cardiovascular risk according to cardiovascular disease and metabolic syndrome
Parameters
Non-CVD group CVD group
P value*
Normal (n = 213) MetS (n = 77) CVD (n = 104) CVD/ MetS (n = 34)
Age (yr)
†  49.81 ± 3.73
a 52.17 ± 3.42
b 49.92 ± 4.17
a 51.53 ± 3.51
a,b < 0.001
Body mass index (kg/m
2) 23.55 ± 2.23
a 23.81 ± 1.96
a  25.88 ± 2.55
b  25.97 ± 2.77
b  < 0.001
Systolic blood pressure (mmHg) 121.53 ± 13.03
a  122.69 ± 13.72
a  131.68 ± 11.19
b  136.56 ± 14.69
b  < 0.001
Diastolic blood pressure (mmHg) 79.99 ± 9.26
a  82.07 ± 9.48
a  87.68 ± 8.19
b  89.66 ± 10.99
b  < 0.001
Waist circumference (cm) 82.64 ± 5.88
a  81.87 ± 5.59
a  89.27 ± 6.06
b  89.09 ± 6.99
b < 0.001
Fasting plasma glucose (mg/dL) 96.65 ± 24.78
a  98.32 ± 18.48
a,b  104.15 ± 15.41
b  104.66 ± 23.35
b  0.036
Total cholesterol (mg/dL) 188.97 ± 32.29
a  190.25 ± 30.77
a  203.72 ± 39.47
b  215.03 ± 26.47
b < 0.001
Triglyceride (mg/dL) 118.58 ± 51.29
a  130.58 ± 82.28
a  218.11 ± 110.45
b  242.13 ± 193.31
b  < 0.001
HDL (mg/dL) 52.75 ± 12.65
a  48.15 ± 11.25
b  45.97 ± 14.51
b  42.29 ± 8.85
c  < 0.001
LDL (mg/dL) 124.53 ± 32.60
a  127.28 ± 29.80
a  132.04 ± 36.71
a  145.50 ± 26.25
b  < 0.001
Homocysteine (µM/L) 10.89 ± 2.86
a  13.11 ± 3.99
b  13.02 ± 3.60
b  14.60 ± 2.92
c  < 0.001
Creatinine (mg/dL) 0.83 ± 0.11  0.84 ± 0.11  0.86 ± 0.10  0.85 ± 0.11  0.148
Dietary folate intake (µg/d)  409.28 ± 184.51 445.81 ± 245.36 386.73 ± 182.82 387.51 ± 222.77 0.231
Dietary vitamin B1 intake (mg/d) 2.01 ± 1.38 2.10 ± 1.30 1.80 ± 1.24 1.64 ± 1.40 0.204
Dietary vitamin B2 intake (mg/d) 1.80 ± 1.10 1.88 ± 1.02 1.60 ± 0.99 1.49 ± 1.11 0.134
Dietary vitamin B6 intake (mg/d) 2.39 ± 1.14 2.57 ± 1.34 2.29 ± 1.28 2.19 ± 1.46 0.358
Data are mean ± standard deviation. *P values were calculated by ANCOVA with adjusted by age; 
†P value was calculated by ANOVA. HDL, high density lipoprotein cholesterol; 
LDL, low density lipoprotein cholesterol. 
a,b,cMeans with each superscript letter are significantly different among four groups.Kang JY, et al.  •  Homocysteine to Predict CVD with or without Mets
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based on the presence of MetS. In non-MetS subjects, the area 
under the curve (AUC) was 0.664 (95% confidence interval [CI], 
0.598-0.731) and Hcy of 11.72 μM was the cut-off point, with a 
sensitivity of 61.5% and a specificity of 62.4% (P < 0.001). Also, 
Hcy cut-off point to predict CVD in MetS subjects was 13.32 μM 
with the best combination of sensitivity (70.6%) and specificity 
(50.6%) yielding the highest Youden index and 0.618 AUC (95% 
CI, 0.509-0.726; P = 0.049).
DISCUSSION
We investigated the usefulness of Hcy for predicting cardiovas-
cular disease in subjects with and without MetS. The cut-off 
points of Hcy, which are 11.72 μM for non-MetS subjects and 
13.32 μM for MetS subjects, are optimal for yielding the maxi-
mal sensitivity plus specificity for predicting CVD.  
  Hcy is known as an independent predictive biomarker for 
CVD (20), causing an increase in oxygen stress and a decrease 
in endothelial function and thus, enhancing thrombotic events 
(5). Hcy levels changed depending on sex, age, smoking and 
intake of coffee, alcohol and folate (9, 21-24). Boushey et al. (20) 
reported that an increase in Hcy for 5 μM/L is associated with 
an odds ratio (OR) for coronary artery disease (CAD) of 1.6 for 
men. Also, several studies demonstrated a relationship between 
Hcy and risk of obesity, diabetes, dyslipidemia, hypertension 
and MetS (25-27), although Veerkamp et al. (28) reported that 
no association was found between plasma Hcy concentration 
and plasma lipid levels, nor between Hcy and insulin resistance. 
In particular, the roles of insulin and/or insulin resistance in de-
termining plasma Hcy have been demonstrated (29).  
  The WC, index of abdominal obesity and one of the compo-
nents of MetS showed positive correlation with Hcy (7, 30), but 
no difference of Hcy level between subjects with WC  ≥ 90 cm 
and with WC < 90 cm (13). Similarly, Koehler et al. (31) report-
ed a weak positive relationship between BMI and Hcy concen-
trations, which was similar to our result. Jacques et al. (24) sug-
gested that persons with BMI  ≥ 30.7 kg/m
2 had slightly higher 
plasma Hcy concentrations than those with a BMI < 30.7 kg/m
2. 
The Hodaland Homocysteine Study investigators reported a U-
shaped association between BMI and Hcy concentrations that 
Table 3. Correlation of homocysteine and cardiovascular risk factors
Risk factors
Correlation coefficient Partial coefficient*
R P value R P value
Age 0.175 < 0.001
Body mass index  0.151 0.002 0.134 0.005
Systolic blood pressure 0.148 0.002 0.125 0.010
Diastolic blood pressure 0.157 0.001 0.141 0.004
Waist circumference 0.142 0.003 0.115 0.018
Fasting plasma glucose 0.121 0.012 0.103 0.034
Total cholesterol 0.118 0.015 0.113 0.020
Triglyceride 0.174 < 0.001 0.168 0.001
HDL -0.120 0.013 -0.108 0.026
LDL 0.089 0.066 0.082 0.090
Creatinine 0.100 0.039 0.110 0.024
*Data are given as Pearson’s correlation (R) coefficients with adjustment for age. HDL, 
high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol.
Table 4. Variables identified by stepwise regression analysis as being predictive of 
CVD in non-MetS and MetS
Variables
Non-MetS (n = 317) MetS (n = 111)
Unstandardized 
coefficients P 
value
Unstandardized 
coefficients P 
value
β SE β SE
Homocysteine 0.041 0.007 < 0.001 0.027 0.013 0.034
HDL -0.006 0.002   0.003
Adjusted R
2                  0.114 0.032
Data are regression coefficient. SE, standard error; HDL, high density lipoprotein cho-
lesterol.
Fig. 1. Receiver-operating-characteristic curves of Hcy for CVD according to the (A) non-MetS subjects, (B) MetS subjects.   
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disappeared after adjustment for other determinants of Hcy con-
centrations (32). Lim et al. (15) suggested that we should use a 
different index and standard of defining obesity according to 
ethnicity as well as East and West affiliation, because people 
with different ethnicities have different characteristics of obesi-
ty. We agreed with this opinion, and large-scale prospective stud-
ies are needed to establish a suitable index and standard of obe-
sity for Korean.     
  Like our result, positive association between Hcy and blood 
pressure was reported in several studies (13, 22, 24, 32). How-
ever, Sun et al. (6) found negative correlation and Shin et al. (9) 
reported no correlation between Hcy and blood pressure. 
  Hcy and lipid metabolism were interrelated at least in part 
via methyl group donors (33). Moreover, hyperhomocystein-
emia in mice was associated with a decreased activity of hepat-
ic thiolase and serum lecithin-cholesteol acylransferase (LCAT), 
which are two important enzymes involved in HDL metabolism 
(34). Real et al. (27) and Obeid and Herrmann (33) showed sig-
nificant negative correlation between Hcy and HDL, but no cor-
relations with other lipid profiles. In our study, a relationship 
was found between Hcy levels and the lipid profile (TC, TG and 
HDL), except for LDL.
  B vitamins (vitamin B1, B2, B6, B12, and folate) are involved in 
homocysteine metabolism (35). In addition, numerous obser-
vational studies suggested that B vitamins may provide a pro-
tective effect due to the Hcy-lowering effect (36). Chang et al. 
(37) showed that the dietary intake of folate, thiamin (vitamin 
B1), riboflavin (vitamin B2) and vitamin C were inversely associ-
ated with the risk of hyperhomocysteinemia in diabetic patients. 
In this study, the intakes of vitamin B1 and B2 were significantly 
low in CVD subjects, although there was no significant relation 
between Hcy and B vitamins (data not shown). Therefore, the 
deficiency of vitamin B2 could cause a secondary deficiency in 
folate (38), leading to an increase of plasma Hcy. Although plas-
ma folic acid and vitamim B12 were not measured in this study, 
none of the patients had a history or laboratory evidence of ane-
mia attributable to low plasma folate and vitamim B12.     
  There are just 3 published studies of CVD outcomes related 
to Hcy levels in men (mean age about 50 yr) (28, 39, 40). The 
mean Hcy level among controls in the different studies varied 
from 9.9 μM to 10.9 μM. In this study, Hcy levels of 10.89 μM 
were similar to other results in the control group, but the non-
CVD group had higher Hcy levels of 11.45 μM. This may be be-
cause the non-CVD group included subjects with MetS. Previ-
ous observations and our study indicated that individuals with 
MetS a had higher Hcy level than control subjects (9, 13). Ntaios 
et al. (25) found that several drugs used in MetS patients influ-
ence Hcy levels. Therefore, to determine the optimal cut-off 
point of Hcy for CVD, we must consider the presence of MetS 
or the medication usage for the subjects.  
  A variety of large-scale prospective cohorts have specified 
only 1 vascular disease: stroke (10) or coronary heart disease 
(8). Moreover, there was no agreement on the cut-off point for 
the diagnosis of hyperhomocysteinemia, and there are few stud-
ies that suggested optimal cut-off point by Youden’s index. We 
determined that 11.72 μM in non-MetS and 13.32 μM in MetS 
may be the optimal cut-off point for CVD. These values that were 
higher than 9.47 μM were the most appropriate cut-off point 
value of Hcy for cardiovascular events by Sun et al. (6). Despite 
Hcy being influenced by sex, Sun et al. (6) have not suggested a 
cut-off point of Hcy for CVD according to sex.
  This study had a limitation because of the challenges with inter-
preting data in a case-control study to determine the optimal cut-
off point. Although the discriminatory poser of our study was suf-
ficient, the non-CVD group was selected by a matching method. 
  The strength of this study was that it was a large-scale study 
conducted in a comparatively short period. It is difficult to con-
duct an epidemiological study on CVD. Because the incremental 
costs of diagnosis for CVD, such as computed tomography (CT), 
treadmill test (TMT) and coronary arteriography (CAG), were 
huge. Also, diagnosis of CVD could take long to gather sufficient 
CVD cases. Nevertheless, our findings identified important issues 
for further study and provided possible explanations for impor-
tant clinical findings on relationships among Hcy, MetS and CVD.  
  In conclusion, this study shows that the cut-off value of Hcy 
for predicting the CVD is influenced by presence of MetS. A 
prospective longitudinal study would be necessary to address 
these issues as well as to identify factors determining the Hcy 
level in response to the development of CVD with or without 
MetS. In addition, the feasibility of incorporating Hcy in clinical 
screening for primary prevention warrants further research.
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